LYEL — Lyell Immunopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1806952 ·
Last close
$9.85
Market Cap
$241.38M
52W High
$45.00
52W Low
$9.81
ADV30
133,230
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 4,000 | — | -47,337,000 | -44,755,000 | 311,153,000 | 72,985,000 | 77,338,000 |
| Mar 2026 | 2,000 | — | -44,261,000 | -24,153,000 | 350,626,000 | 90,770,000 | 76,961,000 |
| Dec 2025 | 6,000 | — | -61,312,000 | -140,723,000 | 340,052,000 | 60,181,000 | 91,850,000 |
| Sep 2025 | 15,000 | — | -37,253,000 | -38,846,000 | 407,965,000 | 123,575,000 | 78,844,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-133,260,000
Investing CF
$4,978,000
Financing CF
$102,466,000
CapEx
$-711,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.77
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,688,462,000
Inventory
—
Receivables
—
ST Investments
$131,117,000
EBIT TTM
$-190,163,000
Pretax Income TTM
$-248,477,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$27,000
EBITDA
$-180,944,000
Free Cash Flow
$-72,809,128
Enterprise Value
$135,577,488
Total Cash
$204,102,000
Total Debt
$46,598,000
Shares Out
24,505,141
Trailing EPS
$-12.69
Book Value
$9.99
ROE
-93.3%
ROA
-34.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 36,000 | -201,629,000 | -274,448,000 | 340,052,000 | 91,850,000 | 248,202,000 | -150,024,000 |
| Dec 2024 | 61,000 | -220,274,000 | -342,994,000 | 490,859,000 | 108,035,000 | 382,824,000 | -162,394,000 |
| Dec 2023 | 130,000 | -247,008,000 | -234,632,000 | 750,029,000 | 95,077,000 | 654,952,000 | -163,694,000 |
| Dec 2022 | 84,683,000 | -187,058,000 | -183,118,000 | 937,561,000 | 104,309,000 | 833,252,000 | -169,555,000 |
TTM Snapshot
Revenues TTM
$13,000
NetIncome TTM
$-45,809,000
OpCashFlow TTM
$0
Assets (Latest)
$490,859,000
Forward EPS
$-6.32
Max Pain — expiry 2026-10-16
max pain strike: $13.00 · spot: $9.85 · call oi: 120 · put oi: 2,131Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | $239.85M | $6.16 | — |
| PYXS | Pyxis Oncology, Inc. | $238.55M | $2.86 | — |
| MGNX | MACROGENICS INC | $238.24M | $3.74 | — |
| CAMP | Camp4 Therapeutics Corp | $245.99M | $3.92 | — |
| SION | Sionna Therapeutics, Inc. | $236.14M | $5.23 | — |
News headlines (Yahoo Finance, 1h cache)
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
2026-09-10 20:05 · Yahoo
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
2026-07-02 13:55 · Yahoo
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-25 12:00 · Yahoo
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Cong
2026-06-12 16:45 · Yahoo
Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?
2026-06-09 10:49 · Yahoo
Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study
2026-06-08 10:46 · Yahoo
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
2026-06-08 10:00 · Yahoo
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-06-04 13:35 · Yahoo
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-06-01 12:00 · Yahoo
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)
2026-05-19 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.